Martine Rothblatt, United Therapeutics CEO (Jack Plunkett/AP Images)
When a citizen petition works: FDA's review of United Therapeutics' PAH drug extended to May
Nearly every time a biopharma company or its law firm files a citizen petition to delay a new or generic drug’s approval, the petition is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
